# Ionis Pharmaceuticals Wins Positive EU CHMP Opinion for TRYNGOLZA in Severe Hypertriglyceridemia

- URL: https://stocks.freetheai.org/news/ionis-pharmaceuticals-wins-positive-eu-chmp-opinion-for-tryngolza-in-severe-7e3b22
- Published: 2026-10-16T10:45:00Z
- Category: company_news; sentiment: bullish; impact: medium
- Symbols: [NASDAQ:IONS](https://stocks.freetheai.org/symbols/NASDAQ-IONS)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

European regulators issued an early positive opinion recommending approval for TRYNGOLZA (olezarsen), an investigational therapy developed by Ionis Pharmaceuticals, Inc. (IONS). The recommendation covers adult patients with severe hypertriglyceridemia, defined by triglyceride levels of 880 mg/dL or higher. Shares of Ionis Pharmaceuticals, Inc. rose 3.33% to $44.12 following the development.

If granted final authorization, TRYNGOLZA would mark the first RNA-targeted therapy available in the European Union for severe hypertriglyceridemia, a condition affecting an estimated 700,000 people in major European nations. Phase 3 clinical data demonstrated that the treatment reduced triglyceride levels by up to 72% at six months while achieving an 85% reduction in acute pancreatitis events.

A binding approval decision from the European Commission is expected in the fourth quarter of 2026. Investors will monitor the regulatory outcome alongside commercial launch plans, pricing strategies, and coverage agreements with European distribution partner Sobi.

## Key points

- European regulators recommended EU approval for TRYNGOLZA to treat severe hypertriglyceridemia ahead of schedule.
- A binding decision from the European Commission is expected in the fourth quarter of 2026.
- Phase 3 trial results showed up to a 72% reduction in triglycerides at six months and an 85% drop in pancreatitis events.
- Ionis Pharmaceuticals, Inc. (IONS) stock rose 3.33% to $44.12 following the announcement.

## Questions and answers

### What is the EU regulatory status of TRYNGOLZA?

European regulatory advisers issued a positive opinion recommending approval for TRYNGOLZA to treat adults with severe hypertriglyceridemia. A final European Commission decision is expected in the fourth quarter of 2026.

### How effective was TRYNGOLZA in clinical trials?

In Phase 3 clinical trials, TRYNGOLZA reduced triglyceride levels by up to 72% at six months and led to an 85% drop in acute pancreatitis events.

### What is the target patient population for TRYNGOLZA in Europe?

TRYNGOLZA targets adults with severe hypertriglyceridemia who have triglyceride levels at or above 880 mg/dL, representing approximately 700,000 patients across major European markets.